FDA Approves First Gene Therapy, Hemgenix, for Adults With Hemophilia B

MONDAY, Nov. 28, 2022 -- The U.S. Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec) for the treatment of hemophilia B in adults.
Hemgenix, an adeno-associated virus vector-based gene therapy, is administered via...